The largest study to date testing the ability of the psychedelic compound psilocybin to treat a psychiatric disorder has shown that the mushroom-derived drug, delivered in combination with integrative psychotherapy sessions, significantly reduced participants’ depression as compared to a placebo after three weeks.
If you need to quickly assess whether a patient might have cannabis use disorder, ask them how often they’ve used cannabis in the past year. At least, that is the suggestion put forward in new research published this week.
The certificate was awarded on October 20 to Viridis Laboratories, a cannabis lab in Michigan.
A new study published in the American Journal of Drug and Alcohol Abuse has found that rates of home cultivation are highest in states that permit recreational home cultivation, though the presence of physical cannabis retail stores showed some conflicting associations with home cultivation rates.
The state’s Office of Cannabis Management has removed the pass/fail limits associated with the total yeast and mold counts for cannabis flower and pre-rolls.
Recreational cannabis retailers in New York will have to be separated from the plant’s production under new guidance issued by state regulators.
Regulators in Colorado have found “potentially unsafe” levels of Aspergillus mold on batches of medical cannabis flower.
The researchers argue that the medical establishment should find a new approach to determining transplant candidacy for cannabis users.
Germany’s full legalization plan has been revealed by the country’s health minister.
Pennsylvania’s cannabis regulator recently approved the “final regulations” for the state’s medical cannabis program – and the new rules include one controversial requirement.